Abstract: This invention relates to a pharmaceutical preparation comprising nicotinamide in combination with phosphate lowering agents (phosphate binders) for the treatment of elevated serum phosphate levels resulting particularly from kidney failure, especially in patients undergoing hemodialysis treatment, as well as to a pharmaceutical composition comprising a pharmaceutically effective amount of a combination of nicotinamide with phosphate binders together with pharmaceutically acceptable carriers.

Abstract: The present invention relates to a pharmaceutical preparation comprising modified release nicotinamide, as well as its use in a method of preventing and/or treating of elevated serum phosphate levels (hyperphosphatemia) and/or dyslipidemia, both particularly resulting from renal failure.

Abstract: Described herein is a pharmaceutical composition comprising atropine or a salt thereof; aconitine; and mercury cyanide. The composition is useful in a method for treating a viral infection.

Abstract: The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nanoparticle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method.

Abstract: Described herein is a pharmaceutical composition comprising atropine or a salt thereof; aconitine; and mercury cyanide. The composition is useful in a method for treating a viral infection.

Abstract: The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nano particle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method.

Abstract: The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives. The invention further relates to a process for preparing a pharmaceutical composition which comprises bendamustine and its derivatives prepared by hot melt extrusion using pharmaceutically acceptable excipients. The invention also relates to such pharmaceutical compositions and hot melt extrudates.

Abstract: The invention provides a culture device comprising a plurality of culture units, wherein each unit comprises a culture chamber, an inlet port for liquid supply of the culture and an outlet port for discharging liquid from the unit, wherein the inlet port is in fluid communication with the culture chamber and the culture chamber is in fluid communication with the outlet port for allowing a liquid flow through the culture chamber. The culture device is particularly suitable for testing immune cells and immunofunction in vitro. Aspects of the invention include a culture device and associated methods for cultivating immune cells and an in vitro method of analysing the effect of a test compound on immune cells.

Abstract: The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.

Abstract: The invention provides a culture device comprising a plurality of culture units, wherein each unit comprises a culture chamber, an inlet port for liquid supply of the culture and an outlet port for discharging liquid from the unit, wherein the inlet port is in fluid communication with the culture chamber and the culture chamber is in fluid communication with the outlet port for allowing a liquid flow through the culture chamber. The culture device is particularly suitable for testing immune cells and immunofunction in vitro. Aspects of the invention include a culture device and associated methods for cultivating immune cells and an in vitro method of analysing the effect of a test compound on immune cells.

Abstract: The invention relates to the use of sweeteners for masking the salty taste of compositions as well as compositions containing salt and defined sweeteners, the amount of sweeteners being suitable for masking the salty taste of the composition.

Abstract: The invention provides a culture system, which combines a device for undifferentiated proliferation of the cells with a device for cell differentiation and proliferation. Aspects of the invention include a modular culture system, a kit and an associated method for combining undifferentiated proliferation of cells with differentiation and proliferation of cells in a single, integrated device. The culture system has a first compartment comprising a plurality of miniaturized culture cavities that are sealed on one end by a surface that may be perforated, and a second compartment which defines one or more, larger culture chambers, and wherein said first and second compartment can be sterilely connected and living cell material can be transferred directly and in a controlled manner from the first compartment into the second compartment.

Abstract: The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.